US FDA Gives Directions On Navigating Generic 180-Day Exclusivity Maze

Draft guidance sums up agency’s policies for determining exclusivity, clarifies when the clock starts for failure to market.

FDA entrance sign 2016

More from US FDA

More from Agency Leadership